ROCKET PHARMACEUTICALS HIGHLIGHTS FDA-ALIGNED PIVOTAL PHASE 2 TRIAL AND UPDATED CLINICAL FINDINGS FOR RP-A501 FOLLOWING DANON DISEASE INVESTOR WEBINAR

Reuters · 1d ago

Please log in to view news